Q3 2025 Financial Results
Access all the information about Grifols' Q3 Financial Results.
Showing 247 search results
Egypt achieves self-sufficiency in plasma-derived medicines thanks to Grifols
Grifols appoints Tomás Dagá as Vice President of the board of Grifols Egypt (GEPD) and accelerates plasma self-sufficiency for 2026
Grifols brings together companies and organizations to address the challenges of employment for people with disabilities
Grifols receives expanded indication for THROMBATE III® (antithrombin III [human]) label in U.S., strengthening treatment options for pediatric patients
Grifols’ Biotest receives first regulatory approval for its fibrinogen concentrate
Grifols Secures 95% of Investor Support to Improve Documentation Terms of Its €1.3 Billion 7.5% Secured Notes
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings annual report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.